GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Trial Details

NCT ID
NCT06875063
Phase
PHASE1
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • GB5005 CART
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • The candidate is able to communicate effectively with researchers and sign informed consent forms in writing;
  • Age greater than or equal to 18 years old and less than or equal to 70 years old, regardless of gender; Sign informed consent form;
  • Non Hodgkin lymphoma confirmed by cytology and genetics;
  • Positive expression of CD19 in tumor cells confirmed by flow cytometry or pathological histology;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →